Routine share-reward plan transactions with no discretionary signal. Ignore for trading purposes; no follow-up required.
GSK drugs
GSK drug pipeline →How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Jun 11 $52.86entry
- T+1 · 5mo ago +0.34%α −0.20% · $53.04
- T+5 · 5mo ago −1.34%α −1.78% · $52.15
- T+20 · 4mo ago −0.74%α −2.63% · $52.47
- T+60 · 2mo ago −5.62%α −10.01% · $49.89
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
GSK filed a routine Form 6-K on June 11, 2026, disclosing eight PDMR transactions under the company's Share Reward Plan. Seven senior executives and one PCA acquired a total of 110 ordinary shares at £18.8393 per share on June 9, 2026. These are formulaic, pre-planned plan acquisitions, not discretionary open-market buys, with trivial aggregate value (~£2,070). The filing carries no material financial or strategic content.
Key Facts
- Filed June 11, 2026, reporting transactions from June 9, 2026.
- Eight PDMRs/PCA acquired shares: Lynn Baxter, Julie Brown (CFO), James Ford, David Redfern, Regis Simard, Philip Thomson, Deborah Waterhouse, Victoria Whyte, and Neil Falkingham (PCA of Lynn Baxter).
- Type: acquisition under GSK's Share Reward Plan (partnership + matching shares).
- Share price: £18.8393 per share; individual acquisitions range from 12 to 14 shares.
- Total shares acquired: 110 ordinary shares; total consideration approximately £2,072 in GBP.
- All transactions on the London Stock Exchange (XLON).
- No open-market discretionary purchases; no sales reported.
Financial Impact
Trivial, aggregate value approximately £2,072 (110 shares × £18.8393), immaterial for a ~£104B market cap company.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001654954-26-005880 |
| Document: 0001654954-26-005880-index-headers.html | 0001654954-26-005880 |
| Document: 0001654954-26-005880-index.html | 0001654954-26-005880 |
| Document: 0001654954-26-005880.txt | 0001654954-26-005880 |
Track record
64 reports on GSK
9 of 18 bullish or bearish reports moved the stock their way by T+20. Best: +9.35% at T+60 after the Jul 17, 2026 report. 15 of 21 went positive at some point.
Filters
- Nov 13, 20263d ago 6-K Neutral 4/10 Entry $50.45 Now $50.41 −0.08% settles Dec 14
- Nov 12, 20264d ago 6-K Neutral 2/10 Entry $50.64 Now $50.41 −0.45% settles Dec 11
- Nov 6, 202610d ago 6-K Neutral 1/10 Entry $50.33 Now $50.41 +0.16% settles Dec 7
- Nov 2, 202614d ago 6-K Neutral 1/10 Entry $49.13 Now $50.41 +2.61% settles Dec 1
- Oct 28, 202619d ago 6-K Neutral 5/10 Entry $48.74 Now $50.41 +3.43% settles Nov 25
- Oct 26, 202621d ago 6-K Bullish 5/10 Entry $51.10 Now $50.41 −1.35% settles Nov 23
- Oct 26, 202621d ago 6-K Neutral 1/10 Entry $51.10 Now $50.41 −1.35% settles Nov 23
- Oct 26, 202621d ago 6-K Bullish 5/10 Entry $51.10 Now $50.41 −1.35% settles Nov 23
- Oct 26, 202621d ago 6-K Neutral 4/10 Entry $51.10 Now $50.41 −1.35% settles Nov 23
- Oct 21, 202626d ago 6-K Bullish 7/10 Entry $50.02 Now $50.41 +0.78% settles Nov 18
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers